[go: up one dir, main page]

PE20220341A1 - Derivados de quinazolin-4-ona utiles en el tratamiento de enfermedades y trastornos asociadas con braf - Google Patents

Derivados de quinazolin-4-ona utiles en el tratamiento de enfermedades y trastornos asociadas con braf

Info

Publication number
PE20220341A1
PE20220341A1 PE2021002078A PE2021002078A PE20220341A1 PE 20220341 A1 PE20220341 A1 PE 20220341A1 PE 2021002078 A PE2021002078 A PE 2021002078A PE 2021002078 A PE2021002078 A PE 2021002078A PE 20220341 A1 PE20220341 A1 PE 20220341A1
Authority
PE
Peru
Prior art keywords
alkyl
braf
optionally substituted
independently selected
dihydroquinazolin
Prior art date
Application number
PE2021002078A
Other languages
English (en)
Inventor
Patrick Michael Barbour
Katie Keaton Brown
Adam Wade Cook
Erik James Hicken
Dean Russell Kahn
Ellen Ruth Laird
Andrew Terrance Metcalf
David Austin Moreno
Bradley Jon Newhouse
Spencer Phillip Pajk
Brett Joseph Prigaro
Li Ren
Eugene Tarlton
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of PE20220341A1 publication Critical patent/PE20220341A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

En la presente se proveen compuestos de la formula I, en donde L es O, NH o S; X1 es CH o N; R1 es alquilo de C1-C6, deuteroalquilo de C1-C6, fluoroalquilo de C1-C6, cicloalquilo de C3-C6, (cicloalquilo de C3-C6)CH2-, (alcoxi de C1-C6)alquilo de C1-C6, Ar1 , entre otros; Ar1 es fenilo que esta opcionalmente sustituido con 1-5 sustituyentes seleccionados independientemente de halogeno y alquilo de C1-C3; R2 es metilo, -CD3 o HC?C-; R3 es F, Cl, CN o metilo; R4 es H, F o Cl; R5 es H, F, Cl o metilo; R6 es alquilo de C1-C6, fluoroalquilo de C1-C6, (Cyc1 )alquilo de C1-C6, (alcoxi de C1-C3)alquilo de C1-C6, hetAr2 , Ar2 o RaRbN-; Cyc1 es un anillo carbociclico saturado de 3-6 miembros; hetAr2 es un heteroarilo de 5-6 miembros que tiene 1-2 heteroatomos de anillo seleccionados independientemente de N, O y S y opcionalmente sustituido con 1-3 sustituyentes seleccionados independientemente de halogeno y alquilo de C1-C3; Ar2 es fenilo opcionalmente sustituido con 1-5 sustituyentes seleccionados independientemente de halogeno y alquilo de C1-C6; y Ra y Rb son independientemente alquilo de C1-C3, o Ra y Rb junto con el atomo de nitrogeno al que estan unidos forman un anillo heterociclico saturado monociclico de 5-6 miembros opcionalmente sustituido con 1-2 halogenos. Son compuestos preferidos: N-(3-((3,5-dimetil-4-oxo-3,4-dihidroquinazolin-6-il)amino)-2,4- difluorofenil)propano-1-sulfonamida, N-(3-((3,5-dimetil-4-oxo-3,4-dihidroquinazolin-6-il)amino)-2,4-difluorofenil)-3- fluoropropano-1-sulfonamida, N-(2-cloro-3-((3,5-dimetil-4-oxo-3,4-dihidroquinazolin-6-il)amino)fenil)propano-1- sulfonamida, entre otros. Dichos compuestos son utiles para el tratamiento de enfermedades y trastornos asociados a BRAF, incluyendo tumores asociados a BRAF, incluyendo tumores malignos y benignos asociados a BRAF del SNC y tumores asociados a BRAF extracraneales malignos.
PE2021002078A 2019-06-28 2020-06-24 Derivados de quinazolin-4-ona utiles en el tratamiento de enfermedades y trastornos asociadas con braf PE20220341A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962868581P 2019-06-28 2019-06-28
US202063021410P 2020-05-07 2020-05-07
PCT/IB2020/055992 WO2020261156A1 (en) 2019-06-28 2020-06-24 Quinazolin-4-one derivatives useful for the treatment of braf-associated diseases and disorders

Publications (1)

Publication Number Publication Date
PE20220341A1 true PE20220341A1 (es) 2022-03-14

Family

ID=71465389

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021002078A PE20220341A1 (es) 2019-06-28 2020-06-24 Derivados de quinazolin-4-ona utiles en el tratamiento de enfermedades y trastornos asociadas con braf

Country Status (21)

Country Link
US (2) US11414404B2 (es)
EP (1) EP3990437A1 (es)
JP (1) JP7169469B2 (es)
KR (1) KR102712548B1 (es)
CN (1) CN114026073B (es)
AU (1) AU2020302352B2 (es)
BR (1) BR112021025102A2 (es)
CA (1) CA3144859C (es)
CO (1) CO2021017438A2 (es)
CR (1) CR20210626A (es)
CU (1) CU20210098A7 (es)
EC (1) ECSP21093541A (es)
IL (1) IL288214B2 (es)
MA (1) MA56387A (es)
MX (1) MX2021015903A (es)
PE (1) PE20220341A1 (es)
PH (1) PH12021552913A1 (es)
TW (1) TWI817018B (es)
UY (1) UY38767A (es)
WO (1) WO2020261156A1 (es)
ZA (1) ZA202201329B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI817018B (zh) * 2019-06-28 2023-10-01 美商艾瑞生藥股份有限公司 用於治療ｂｒａｆ相關的疾病和失調症之化合物
HRP20250418T1 (hr) * 2019-12-10 2025-06-06 F. Hoffmann - La Roche Ag Novi derivati metil-kinazolinona
WO2021116050A1 (en) * 2019-12-10 2021-06-17 F. Hoffmann-La Roche Ag New braf inhibitors as paradox breakers
CN113521268A (zh) * 2020-04-22 2021-10-22 生物技术Rna制药有限公司 冠状病毒疫苗
TW202426436A (zh) 2020-06-09 2024-07-01 美商艾瑞生藥股份有限公司 用於治療ｂｒａｆ相關的疾病和病症之化合物
WO2022047145A1 (en) 2020-08-28 2022-03-03 Arvinas Operations, Inc. Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use
TWI825637B (zh) 2021-03-31 2023-12-11 美商輝瑞股份有限公司 啶－１，６（２ｈ，７ｈ）－二酮
KR20240018446A (ko) 2021-06-08 2024-02-13 씨4 테라퓨틱스, 인코포레이티드 돌연변이 braf의 분해를 위한 요법
KR102699226B1 (ko) * 2021-06-09 2024-08-27 에프. 호프만-라 로슈 아게 암 치료를 위한 병용요법
AU2022383040A1 (en) * 2021-11-04 2024-03-07 F. Hoffmann-La Roche Ag Novel use of quinazolinone compound for the treatment of cancer
JP2024545073A (ja) * 2021-12-08 2024-12-05 アレイ バイオファーマ インコーポレイテッド Ｎ－（２－クロロ－３－（（５－クロロ－３－メチル－４－オキソ－３，４－ジヒドロキナゾリン－６－イル）アミノ）－４－フルオロフェニル）－３－フルオロアゼチジン－１－スルホンアミドの結晶形態
WO2023230554A1 (en) 2022-05-25 2023-11-30 Pfizer Inc. Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer
WO2024054591A1 (en) 2022-09-07 2024-03-14 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use
JP2025537786A (ja) * 2022-11-18 2025-11-20 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 進行性固形がんまたは転移の治療のためのｂｒａｆ阻害剤としてのキナゾリノン化合物
WO2024218632A1 (en) 2023-04-17 2024-10-24 Array Biopharma Inc. Erk protein kinase inhibitors
WO2025029683A1 (en) * 2023-07-28 2025-02-06 Cogent Biosciences, Inc. Pi3k inhibitors
WO2025153057A1 (zh) * 2024-01-17 2025-07-24 海思科医药集团股份有限公司 一种含braf抑制剂的药物组合物及其在医药上的应用
WO2025176139A1 (zh) * 2024-02-20 2025-08-28 海思科医药集团股份有限公司 一种喹唑啉酮衍生物的晶型及其制备方法和应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003077914A1 (en) 2002-03-13 2003-09-25 Array Biopharma, Inc N3 alkylated benzimidazole derivatives as mek inhibitors
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
AU2004293018B2 (en) 2003-11-19 2010-02-18 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7732616B2 (en) 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
NZ553087A (en) 2004-08-31 2010-12-24 Astrazeneca Ab Quinazolinone derivatives and their use as B-raf inhibitors
ES2378760T3 (es) 2005-05-18 2012-04-17 Array Biopharma, Inc. Inhibidores heterocíclicos de MEK y métodos de uso de los mismos
CN101415689A (zh) 2006-04-05 2009-04-22 阿斯利康(瑞典)有限公司 具有抗癌活性的经取代的喹唑啉
CN101415688A (zh) 2006-04-05 2009-04-22 阿斯利康(瑞典)有限公司 具有b-raf抑制活性的喹唑啉酮衍生物
WO2007119055A1 (en) 2006-04-18 2007-10-25 Astrazeneca Ab Quinazolin-4-one derivatives, process for their preparation and pharmaceutical compositions containing them
MX2010000617A (es) 2007-07-17 2010-05-17 Plexxikon Inc Compuestos y metodos para modulacion de cinasa, e indicaciones de estos.
WO2012118492A1 (en) * 2011-03-01 2012-09-07 Array Biopharma Inc. Heterocyclic sulfonamides as raf inhibitors
US11007194B2 (en) 2011-11-11 2021-05-18 Array Biopharma Inc. Method of treating a proliferative disease
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
ES2699354T3 (es) 2014-01-17 2019-02-08 Novartis Ag Derivados de 1-(triazin-3-il/piridazin-3-il)-piper(-azin)idina y composiciones de las mismas para inhibir la actividad de SHP2
ES2699351T3 (es) 2014-01-17 2019-02-08 Novartis Ag Derivados de 1-piridazin/triazin-3-il-piper(-azina)/idina/pirolidina y composiciones de las mismas para inhibir la actividad de SHP2
AU2017204973A1 (en) 2016-01-06 2018-07-12 Trillium Therapeutics Inc. Novel fluorinated quinazoline derivatives as EGFR inhibitors
JP7219218B2 (ja) 2016-12-22 2023-02-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規のベンジルアミノ置換キナゾリンおよびｓｏｓ１阻害剤としての誘導体
EP3684772B1 (en) 2017-09-20 2023-12-06 ABM Therapeutics Corporation Cyclic iminopyrimidine derivatives as kinase inhibitors
WO2019071351A1 (en) 2017-10-12 2019-04-18 Trillium Therapeutics Inc. NOVEL 4-ARYLOXYQUINAZOLINE FLUORIN DERIVATIVES AS EGFR INHIBITORS USEFUL FOR THE TREATMENT OF CANCERS
EP3694848A1 (en) 2017-10-12 2020-08-19 Revolution Medicines, Inc. Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors
UY38349A (es) 2018-08-30 2020-03-31 Array Biopharma Inc Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met
MX2021002880A (es) 2018-09-14 2021-06-04 Unilever Ip Holdings B V Evaluacion de la eficacia de composiciones cosmeticas que no se deben enjuagar para proteger la piel de los contaminantes.
TWI817018B (zh) * 2019-06-28 2023-10-01 美商艾瑞生藥股份有限公司 用於治療ｂｒａｆ相關的疾病和失調症之化合物

Also Published As

Publication number Publication date
TW202114996A (zh) 2021-04-16
CO2021017438A2 (es) 2022-01-17
US20220289721A1 (en) 2022-09-15
BR112021025102A2 (pt) 2022-01-25
EP3990437A1 (en) 2022-05-04
IL288214B1 (en) 2024-11-01
KR20220011712A (ko) 2022-01-28
PH12021552913A1 (en) 2022-04-04
MX2021015903A (es) 2022-02-03
WO2020261156A1 (en) 2020-12-30
TWI817018B (zh) 2023-10-01
KR102712548B1 (ko) 2024-09-30
CN114026073A (zh) 2022-02-08
CA3144859A1 (en) 2020-12-30
JP2022539056A (ja) 2022-09-07
IL288214B2 (en) 2025-03-01
AU2020302352B2 (en) 2023-03-23
CR20210626A (es) 2022-02-08
JP7169469B2 (ja) 2022-11-10
CA3144859C (en) 2023-09-12
CU20210098A7 (es) 2022-06-06
IL288214A (en) 2022-01-01
MA56387A (fr) 2022-05-04
CN114026073B (zh) 2024-08-23
ECSP21093541A (es) 2022-01-31
AU2020302352A1 (en) 2022-01-20
US20200407344A1 (en) 2020-12-31
US11634409B2 (en) 2023-04-25
US11414404B2 (en) 2022-08-16
UY38767A (es) 2021-01-29
ZA202201329B (en) 2023-09-27

Similar Documents

Publication Publication Date Title
PE20220341A1 (es) Derivados de quinazolin-4-ona utiles en el tratamiento de enfermedades y trastornos asociadas con braf
PE20240143A1 (es) Nuevos derivados de quinazolina como inhibidores de sos1 y uso de los mismos
CO2022008091A2 (es) Inhibidores de kras g12c
PE20221264A1 (es) Inhibidores de egfr
PE20221253A1 (es) Inhibidores de pequenas moleculas de mutante g12c de kras
ECSP23095485A (es) N-(hidroxialquil (hetero)aril) tetrahidrofurano carboxamidas como moduladores de canales de sodio
AR112529A1 (es) Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos en el tratamiento de diversos tipos de cáncer
AR062299A1 (es) Derivados de bencimidazol
CL2020000029A1 (es) Nuevos compuestos de carboxamida sulfonamida.
PE20212302A1 (es) Inhibidores de apol1 y sus metodos de uso
AR029301A1 (es) Compuestos derivados de biarilo, metodos para su preparacion composiciones que los contienen, su uso como agonistas en receptores beta-adreno-receptores atipicos
PE20020753A1 (es) Heteroaromaticos fusionados como activadores de la glucoquinasa
PE20050767A1 (es) Amino-benzazoles como inhibidores del receptor p2y1
PE20030447A1 (es) Derivados n-(1,4,5,6-tetrahidro-ciclopentapirazol-3-il)-sustituidos y su obtencion
AR063128A1 (es) Compuestos de aril - indol sustituido y sus usos metabolitosde tipo quinurenina / quinurenina como agentes terapeuticos
PE20070855A1 (es) Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
CY1125335T1 (el) Ετεροαρυλικες ενωσεις ως αναστολεας κινασης
PE20030417A1 (es) Derivados de urea como antagonistas del receptor vainilloide
AR099379A1 (es) Compuestos tricíclicos como agentes antineoplásicos
PE20160548A1 (es) Sulfonamidas como moduladores de canales de sodio
AR033379A1 (es) Compuestos de difenilurea, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
AR054035A1 (es) Derivados benzodioxano y benzodioxolano y uso de los mismos
PE20211388A1 (es) Compuestos
AR099498A1 (es) Compuestos de triazina y su uso farmacéutico
CY1119371T1 (el) Υποκατεστημενες ενωσεις καρβοξαμιδιων τετραϋδροκαρβαζολης και καρβαζολης χρησιμες ως αναστολεις κινασων